Our Pipeline

Robust, focused, exciting in its potential.

Our pipeline centers on promising internally developed compounds.

Each was discovered by our own people. Each targets proven pathways to disrupting cancer growth. Each has potential for important patient impact.

Our Pipeline

Iclusig® (ponatinib)*

Product: CML, Ph+ ALL (refractory)
Phase: PreclinicalProof of ConceptPivotalApproved
Product: Ph+ ALL (with chemo, 1st, 2nd line)
Phase: PreclinicalProof of ConceptPivotalApproved
Product: AML (FLT3)
Phase: PreclinicalProof of ConceptPivotalApproved
Product: Lung cancer (FGFR)
Phase: PreclinicalProof of ConceptPivotalApproved
Product: Lung cancer (RET)
Phase: PreclinicalProof of ConceptPivotalApproved
Product: Gastrointestinal stromal tumors (KIT)
Phase: PreclinicalProof of ConceptPivotalApproved
Product: Medullary thyroid cancer (RET)
Phase: PreclinicalProof of ConceptPivotalApproved
Product: Biliary cancer (FGFR)
Phase: PreclinicalProof of ConceptPivotalApproved
Product: Non-small cell lung cancer (ALK)
Phase: PreclinicalProof of ConceptPivotalApproved
Product: Non-small cell lung cancer
Phase: PreclinicalProof of ConceptPivotalApproved

* Includes investigator-sponsored trials.
In some trials, enrollment of new patients is on hold.

Iclusig: Click here for full U.S. prescribing information and Medication Guide (PDF), including Boxed Warning.